Alan Menter Selected Research

Psoriasis (Pustulosis Palmaris et Plantaris)

03/2008	Utilization of narrow-band ultraviolet light B therapy and etanercept for the treatment of psoriasis (UNITE): efficacy, safety, and patient-reported outcomes.
02/2008	Safety and efficacy of ABT-874, a fully human interleukin 12/23 monoclonal antibody, in the treatment of moderate to severe chronic plaque psoriasis: results of a randomized, placebo-controlled, phase 2 trial.
01/2008	Safety of Efalizumab Therapy in Patients with Moderate to Severe Psoriasis: An Open-Label Extension of a Phase IIIb Trial.
01/2008	Alefacept revisited: Our 3-year clinical experience in 200 patients with chronic plaque psoriasis.
01/2008	Adalimumab therapy for moderate to severe psoriasis: A randomized, controlled phase III trial.
06/2007	Transitioning patients from efalizumab to alternative psoriasis therapies: findings from an open-label, multicenter, Phase IIIb study.
04/2007	Calcitriol 3 microg/g ointment in the management of mild to moderate plaque type psoriasis: results from 2 placebo-controlled, multicenter, randomized double-blind, clinical studies.
01/2007	A randomized comparison of continuous vs. intermittent infliximab maintenance regimens over 1 year in the treatment of moderate-to-severe plaque psoriasis.
01/2007	Impact of adalimumab treatment on patient-reported outcomes: Results from a Phase III clinical trial in patients with moderate to severe plaque psoriasis.
05/2006	Safety of efalizumab in adults with chronic moderate to severe plaque psoriasis: a phase IIIb, randomized, controlled trial.
04/2006	Long-term management of plaque psoriasis with continuous efalizumab therapy.
01/2006	A review of malignancies observed during efalizumab (Raptiva) clinical trials for plaque psoriasis.
01/2006	The efficacy of multiple courses of alefacept in patients with moderate to severe chronic plaque psoriasis.
03/2005	Extended efalizumab therapy improves chronic plaque psoriasis: results from a randomized phase III trial.
03/2005	Efalizumab: continuous therapy for chronic psoriasis.
01/2005	Efficacy and safety observed during 24 weeks of efalizumab therapy in patients with moderate to severe plaque psoriasis.
12/2004	The effect of psoriasis on patients' quality of life and improvements associated with alefacept therapy.
11/2004	Pimecrolimus cream 1% in the treatment of intertriginous psoriasis: a double-blind, randomized study.
10/2004	Psoriasis and its treatment with infliximab-mediated tumor necrosis factor alpha blockade.
10/2004	Infliximab induction therapy for patients with severe plaque-type psoriasis: a randomized, double-blind, placebo-controlled trial.
04/2004	Evaluation of safety and clinical activity of multiple doses of the anti-CD80 monoclonal antibody, galiximab, in patients with moderate to severe plaque psoriasis.
01/2004	Impact of efalizumab on psoriasis-specific patient-reported outcomes. Results from three randomized, placebo-controlled clinical trials of moderate to severe plaque psoriasis.
12/2003	Efalizumab for patients with moderate to severe plaque psoriasis: a randomized controlled trial.
12/2003	Treatment of psoriasis with alefacept: correlation of clinical improvement with reductions of memory T-cell counts.
09/2003	Changing paradigms in dermatology: tumor necrosis factor alpha (TNF-alpha) blockade in psoriasis and psoriatic arthritis.
04/2003	Modulating T cell responses for the treatment of psoriasis: a focus on efalizumab.
03/2003	Repeat courses of intravenous alefacept in patients with chronic plaque psoriasis provide consistent safety and efficacy.
01/2003	Novel immunoglobulin superfamily gene cluster, mapping to a region of human chromosome 17q25, linked to psoriasis susceptibility.
05/2002	A randomized, double-blind, placebo-controlled study of clobetasol propionate 0.05% foam in the treatment of nonscalp psoriasis.

Articles by Research Topic

Disease

29	Psoriasis (Pustulosis Palmaris et Plantaris) 03/2008 - 05/2002
2	Keratosis 06/2008 - 08/2002
1	Acne Vulgaris 06/2007
1	Melanosis (Freckles) 03/2004
1	Psoriatic Arthritis 09/2003
1	Seborrheic Dermatitis 09/2003
1	Tinea Pedis (Athlete's Foot) 09/2003

Drug/Important Bio-Agent (IBA)

11	efalizumab FDA Link 01/2008 - 04/2003
5	alefacept (Amevive)FDA Link 01/2008 - 03/2003
3	infliximab (Remicade)FDA Link 01/2007 - 10/2004
2	Fluorouracil (Carac)FDA LinkGeneric 06/2008 - 08/2002
2	adalimumab (Humira)FDA Link 01/2008 - 01/2007
2	Tumor Necrosis Factor-alpha (Tumor Necrosis Factor)IBA 10/2004 - 09/2003
2	ciclopirox (Loprox)FDA LinkGeneric 09/2003 - 09/2003
1	TNFR-Fc fusion protein (etanercept)FDA Link 03/2008
1	Interleukin-12 (IL 12)IBA 02/2008
1	Tretinoin (Retinoic Acid)FDA LinkGeneric 06/2007
1	clindamycin-2-phosphate (Clindets)FDA LinkGeneric 06/2007
1	Calcitriol (Calcijex)FDA LinkGeneric 04/2007
1	pimecrolimus (Elidel)FDA Link 11/2004
1	galiximabIBA 04/2004
1	Adrenal Cortex Hormones (Corticosteroids)IBA 03/2004
1	Immunoglobulins (Immunoglobulin)IBA 01/2003
1	Clobetasol (Clobetasol Propionate)FDA LinkGeneric 05/2002